| USP22 exerts tumor-suppressive functions in colorectal cancer by decreasing mTOR activity | colorectal, |
| Ubiquitin Specific Peptidase 22 Regulates Histone H2B Mono-Ubiquitination and Exhibits Both Oncogenic and Tumor Suppressor Roles in Cancer | None |
| Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma. | thyroid, |
| USP22 acts as an oncogene by regulating the stability of cyclooxygenase-2 in non-small cell lung cancer. | lung, |
| Oncogenic USP22 supports gastric cancer growth and metastasis by activating c-Myc/NAMPT/SIRT1-dependent FOXO1 and YAP signaling. | gastric, |
| USP22 Functions as an Oncogenic Driver in Prostate Cancer by Regulating Cell Proliferation and DNA Repair. | prostate, |
| USP22 acts as an oncogene by the activation of BMI-1-mediated INK4a/ARF pathway and Akt pathway. | None |
| USP22 may act as an oncogene in CRC as it positively regulates cell cycle via both BMI-1-mediated INK4a/ARF pathway and Akt signaling pathway. | None |
| USP22 regulates oncogenic signaling pathways to drive lethal cancer progression. | None |
| findings of the present study suggest a potential mechanism underlying the oncogenic role of USP22 mediated by the modulation of the stability and activity of COX-2 | None |
| USP22 deficiency leads to leukemogenesis through oncogenic Kras activation by a PU.1-dependent mechanism. | None |